The Asia-Pacific (APAC) region is leading in the Parkinson’s disease clinical trial space globally with 44% of trials, according to a new report.
Novotech’s Parkinson’s Disease- Global Clinical Trial Landscape (2024) report finds that, within APAC, China has had the majority share of Parkinson’s disease trials since 2019 at 56%.
Smarter leaders trust GlobalData
APAC was followed by North America, which had 26% of global clinical trials for Parkinson’s disease. The US had the majority with 82% of the trials while Canada accounted for 17% and Mexico 1%.
Europe hosted 25% of Parkinson’s trial activity, led by the UK (with 14% in the region) followed by Russia and Spain (both with 10%). The rest of the world hosted the remaining 5% of trials, of which Israel led the way followed by Iran.
The report draws a correlation between recruitment trends and trial locations, stating: “Since 2019, clinical trials for Parkinson’s disease have exhibited regional differences in recruitment metrics.”
It notes that the US had the longest mean trial duration (15.63 months) while Europe had the shortest (13.28 months). Europe showed high recruitment efficiency according to the report, which identified the region as having faster recruitment durations and patient recruitment rates.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEurope had the highest number of subjects per site per month, with 1.76. The report explains: “Europe’s higher subjects per site per month are due to multi-country trials, providing access to a larger patient population and experienced trial sites.
“Efficient research infrastructure, fewer competing trials than the US and the highest disease incidence help sustain faster and more consistent recruitment compared to the US and Asia-Pacific regions.”
Considering Parkinson’s disease trials in APAC, Novotech’s report states that trial density is five times lower than that of the US and only about half that of Europe. It says: “This highlights the need for scaling up research efforts and more targeted medical interventions in the region.”
The report points to China, Japan and Australia as examples of countries in the APAC region that present “a prime opportunity” for Parkinson’s disease trials as they are representative of the region’s broad patient population. Indeed, these have been the three leading locations within APAC for Parkinson’s disease trials since 2019.
Considering the global Parkinson’s disease picture, the report identified 64 drug candidates in research, with 145 in the preclinical stage and 52 in Phase I trials. It identified another 70 drugs in Phase II trials, which, until yesterday, would have included UCB’s ORCHESTRA study on minzasolmin. The company has now dropped the development of the drug after the study failed to meet its primary and secondary endpoints.
There are seven drug candidates for Parkinson’s disease in Phase III trials. This is alongside 40 drugs already marketed.
According to GlobalData, the diagnosed prevalent cases of Parkinson’s disease in the seven major markets (the US, 5EU (France, Germany, Italy, Spain, the UK), and Japan) are projected to grow at an annual growth rate (AGR) of 1.94% between 2023 to 2033. This represents an increase from 2.64 million to 3.15 million in the period.
GlobalData is the parent company of Clinical Trials Arena.
